Leishmaniasis Thrombin Antagonist
Tech ID
P27-1389
Patent Status
Granted in India
Design Status
--
Technical Description
This invention describes a vorapaxar which acts as a Leishmania donovani Citrate Synthase 5 (LdCS) inhibitor, offering oral treatment potential against Leishmania donovani strain Ag83.
Problems Addressed
- Drug Resistance Issue
- High Treatment Cost
- Severe Side Effects
- Inefficient Drug Delivery
- Limited Oral Therapeutics
- Targets Parasite Life Cycle
TARGET AUDIENCE
- Solar Power Plant Operator Sectors
- Photovoltaic (PV) Module Manufacturing Industry
- Academic & Research Institutions
- Energy and Utility Industries
- Semiconductor & Electronics Manufacturing Industries
TECH FEATURES
- Enhanced Drug Targeting
- Efficient LdCS Inhibition
- Optimized Oral Formulation
- Potent Against Drug-Resistant Strains
- Advanced Parasite Stage Targeting
P27-1389
Send download link to email.
Available For
Available for exclusive and non exclusive license
Sell off
Cost
—
Stage of Developments
Technology Validated
Contact Person
Mr. Lalit Ambastha
IP Bazzaar Technology Pvt. Ltd.
IP Bazzaar Technology Pvt. Ltd.
12 First Floor, National Park, Lajpat Nagar-IV,
New Delhi-110024, India
Tel: [+91] 11-26360036;
Fax: [+91] 11-26360037;
Mobile: [+91]9811367838;
Email: tech@ipbazzaar.com;
www.ipbazzaar.com
New Delhi-110024, India
Tel: [+91] 11-26360036;
Fax: [+91] 11-26360037;
Mobile: [+91]9811367838;
Email: tech@ipbazzaar.com;
www.ipbazzaar.com